Skip to main content
SpringerLink
Log in

Preparing for the New Anticoagulants

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

New anticoagulant agents with differing properties, risks, and potential economic consequences are becoming available. Two subcutaneously injected synthetic pentasaccharide anticoagulants, fondaparinux and idraparinux, employ the minimal chain length required to bind to antithrombin and confer a conformational change, increasing its ability to catalyze inactivation of activated factor X (Xa). Melagatran has also been developed as an injectable drug for markets outside the United States. Recently synthesized oral anticoagulants other than VKAs have proven effective in clinical trials. These drugs do not act by enhancing antithrombin activity, but rather act directly to inhibit the active site of thrombin (melagatran and its orally absorbed derivative, ximelagatran) or factor Xa (razaxaban [DPC-906]). Several studies have been performed with ximelagatran, an oral synthesized pro-drug developed by AstraZeneca, which is rapidly metabolized into the active agent, melagatran.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. van Boeckel CAA, Petitou M. The unique antithrombin III binding domain of heparin: A lead to new synthetic antithrombotics. Agnew Chem Int Ed Engl 1993;32:1671-1690.

    Google Scholar 

  2. Bock SC. Antithrombin III and heparin cofactor II. In: Colman RW, Hirsh J, Marder V, Clowes A, George J, eds. Hemostasis and Thrombosis. Philadelphia: Lippincott William & Wilkins, 2001;326.

    Google Scholar 

  3. Turpie AGG, Gallus AS, Hoek JA. Pentasaccharide investigators.A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001;344:619-625.

    Google Scholar 

  4. Reiter M, Bucek RA, Koca N, Heger J, Minar E. Idraparinux and liver enzymes: Observations from the PERSIST trial. Blood Coagul Fibrinolysis 2003;14:61-65.

    Google Scholar 

  5. Al Dieri R, Wagenvoord R, van Dedem GWK, Beguin S, Hemker HC. Inhibition of blood coagulation by heparins of different molecular weight is caused by a common 54 Davidson functional motif–The C-domain. J Thromb Haemost 2003;1:907-914.

    Google Scholar 

  6. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. A meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002;162:1833-1840.

    Google Scholar 

  7. Eriksson BI, Lassen MR. Pentasaccharide in hip-fracture surgery plus investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: A multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003;163:1337-1342.

    Google Scholar 

  8. Organon-Sanofi-Synthelabo. US FDA approved fondaparinux label, 2003.

  9. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001;119:132S-175S.

    Google Scholar 

  10. Comp PC, Spiro TE, Friedman RJ, et al., Enoxaparin Clinical Trial Group. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement.Enoxaparin Clinical Trial Group. J Bone Joint Surg Am 2001;83-A:336-345.

    Google Scholar 

  11. T Matisse investigators. Fondaparinux in comparison to (low molecular weight) heparin for the initial treatment of symptomatic deep vein thrombosis or pulmonary embolism–The Matisse clinical outcome studies. Blood 2002;100(11 Pt 1):115.

    Google Scholar 

  12. Simoons ML. The PENTUA study: Double-blind dose ranging study of fondaparinux in unstable angina. Circulation 2001;104:1B-4.

    Google Scholar 

  13. Persist investigators. A novel long-acting synthetic factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis, a phase II evaluation. Blood 2002;100(11 Pt 1):115.

    Google Scholar 

  14. Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers.Circulation 2002;106:2550-2554.

    Google Scholar 

  15. Deveras RAE, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 2002;137:884-888.

    Google Scholar 

  16. Gustafsson D, Elg M. Pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite, melagatran: A mini-review.Thromb Res 2003;109(Suppl):S9-S15.

    Google Scholar 

  17. Eriksson BI, Agnelli G, Cohen AT, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003;89:288-296.

    Google Scholar 

  18. Eriksson BI, Agnelli G, Cohen At, et al. Prevention of venous thromboembolism in elective hip or knee replacement surgery. Blood 2002;100(11 Pt 1):82a.

    Google Scholar 

  19. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med 2002;137:648-655.

    Google Scholar 

  20. Colwell CWJr, Berkowitz SD, Davidson BL, et al. Randomized double-blind comparison of ximelagatran and enoxaparin to prevent venous thromboembolism after total hip arthroplasty. Blood 2001;98(11 Pt 1):706a.

    Google Scholar 

  21. Francis CW, Berkowitz SD, Comp PC, et al. Randomized double-blind comparison of ximelagatran and warfarin for prevention of venous thromboembolism after total knee replacement.Blood 2002;100(11 Pt 1):82a.

    Google Scholar 

  22. Eriksson H, Wahlander K, Lundstrom T, et al. Long-term secondary prevention of venous thromboembolism. Blood 2002;100(11 Pt 1) 81a.

    Google Scholar 

  23. Petersen P, Grind M, Adler J. SPORTIF II Investigators.Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: A dose-guiding, tolerability, and safety study. J Am Coll Cardiol 2003;41:1445-1451.

    Google Scholar 

  24. Eriksson H, Wahlander K, Gustafsson D et al. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003;41-47.

  25. Lee W. Drug-induced hepatotoxicity. N Engl J Med 2003;349:474-485.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pulmonary and Critical Care Medicine, Swedish Medical Center and University of Washington School of Medicine, Seattle, WA

    Bruce L Davidson

Authors
  1. Bruce L Davidson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Davidson, B.L. Preparing for the New Anticoagulants. J Thromb Thrombolysis 16, 49–54 (2003). https://doi.org/10.1023/B:THRO.0000014593.16147.bf

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:THRO.0000014593.16147.bf

Search

Navigation